Trials / Completed
CompletedNCT00537862
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients ; A Prospective, Open Label, Multi-center Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
This study will evaluate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in a cyclosporine microemulsion based regimen with C2 monitoring in de novo kidney transplant recipients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric-Coated Mycophenolate Sodium (EC-MPS) |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-02-01
- First posted
- 2007-10-02
- Last updated
- 2017-02-24
Locations
8 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00537862. Inclusion in this directory is not an endorsement.